Literature DB >> 20656379

Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design.

Sundarapandian Thangapandian1, Shalini John, Sugunadevi Sakkiah, Keun Woo Lee.   

Abstract

Over expression of histone deacetylases (HDACs) leads to the suppression of various gene expressions including cancer suppressor gene. Thus, novel inhibitors of these enzymes can be a valid method to treat cancers. To facilitate the discovery of novel HDAC8 inhibitors, pharmacophore models were generated using ligand and receptor based approaches and validated with a database of active and inactive compounds. These validated pharmacophores have effectively been used in search of three databases and final hits were subjected to molecular docking using GOLD 4.1 program. Hit compounds that scored high GOLD fitness scores and showed interactions with catalytically important residues and metal ions were considered. Finally, three compounds have been reported as novel virtual leads to design potent HDAC8 inhibitors. Copyright (c) 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20656379     DOI: 10.1016/j.ejmech.2010.06.024

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  13 in total

1.  Acetylation of heat shock protein 20 (Hsp20) regulates human myometrial activity.

Authors:  Magdalena Karolczak-Bayatti; Michèle Sweeney; Joanna Cheng; Lydia Edey; Stephen C Robson; Scott M Ulrich; Achim Treumann; Michael J Taggart; G Nicholas Europe-Finner
Journal:  J Biol Chem       Date:  2011-07-29       Impact factor: 5.157

2.  Lignin-derived oak phenolics: a theoretical examination of additional potential health benefits of red wine.

Authors:  William N Setzer
Journal:  J Mol Model       Date:  2010-11-16       Impact factor: 1.810

3.  Potent BACE-1 inhibitor design using pharmacophore modeling, in silico screening and molecular docking studies.

Authors:  Shalini John; Sundarapandian Thangapandian; Sugunadevi Sakkiah; Keun Woo Lee
Journal:  BMC Bioinformatics       Date:  2011-02-15       Impact factor: 3.169

4.  Selection of an improved HDAC8 inhibitor through structure-based drug design.

Authors:  Balakrishnan Vijayakumar; Appavoo Umamaheswari; Ayarivan Puratchikody; Devadasan Velmurugan
Journal:  Bioinformation       Date:  2011-09-28

5.  Dynamic structure-based pharmacophore model development: a new and effective addition in the histone deacetylase 8 (HDAC8) inhibitor discovery.

Authors:  Sundarapandian Thangapandian; Shalini John; Yuno Lee; Songmi Kim; Keun Woo Lee
Journal:  Int J Mol Sci       Date:  2011-12-19       Impact factor: 5.923

6.  Search for the pharmacophore of histone deacetylase inhibitors using pharmacophore query and docking study.

Authors:  Atefeh Haji Agha Bozorgi; Afshin Zarghi
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

7.  Mechanistic Insights into the Binding of Class IIa HDAC Inhibitors toward Spinocerebellar Ataxia Type-2: A 3D-QSAR and Pharmacophore Modeling Approach.

Authors:  Siddharth Sinha; Sukriti Goyal; Pallavi Somvanshi; Abhinav Grover
Journal:  Front Neurosci       Date:  2017-01-10       Impact factor: 4.677

8.  Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.

Authors:  Sudhan Debnath; Tanusree Debnath; Samhita Bhaumik; Swapan Majumdar; Arunasree M Kalle; Vema Aparna
Journal:  Sci Rep       Date:  2019-11-20       Impact factor: 4.379

9.  Pharmacophore mapping based inhibitor selection and molecular interaction studies for identification of potential drugs on calcium activated potassium channel blockers, tamulotoxin.

Authors:  R Barani Kumar; M Xavier Suresh
Journal:  Pharmacogn Mag       Date:  2013-04       Impact factor: 1.085

10.  Molecular modeling study on tunnel behavior in different histone deacetylase isoforms.

Authors:  Sundarapandian Thangapandian; Shalini John; Yuno Lee; Venkatesh Arulalapperumal; Keun Woo Lee
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.